Markovitz B P, Randolph A G
Department of Anesthesiology, CCM Washington University of Medicine, St. Louis Children's Hospital, One Children's Place, St Louis, Missouri 63110, USA.
Cochrane Database Syst Rev. 2000(2):CD001000. doi: 10.1002/14651858.CD001000.
Post-extubation stridor may prolong length of stay in the intensive care unit, particularly if airway obstruction is severe and re-intubation proves necessary. Corticosteroids, however, may be associated with adverse effects ranging from hypertension to hyperglycemia, and a more systematic assessment of the efficacy of this therapy is indicated prior to widespread adoption of this practice
To determine whether corticosteroids are effective in preventing or treating post-extubation stridor in critically ill infants, children, or adults.
Controlled trials were identified through MEDLINE, EMBASE and CINAHL. Bibliographies of all identified trials were examined, and authors of included trials were contacted to confirm the methodology and identify other potentially relevant trials.
Any randomized controlled trial that compared administration of corticosteroids by any route with placebo in infants, children, or adults receiving mechanical ventilation via an endotracheal tube in an intensive care unit.
Data from the included studies were extracted independently by two reviewers. The main outcome was the rate of tracheal re-intubation after extubation. The incidence of stridor was examined as a secondary outcome. Subgroup analysis was predetermined to compare preventative use of steroids before extubation and therapeutic use following extubation. Neonates, pediatric patients, and adults were compared separately. A random effects model was used throughout. Methodologic quality of trials was assessed independently by the two reviewers.
Of 251 studies identified, only seven met the criteria for inclusion; three in adults, two in neonates, three in children. All but one examined use of steroids for the prevention of post-extubation stridor; the remaining one concerned treatment of existing post-extubation stridor in children. Patients were drawn from heterogeneous medical/surgical populations. Dexamethasone given intravenously at least once prior to extubation was the most common steroid regimen utilized (uniformly in neonates and children). Prophylactic intervention tended to decrease re-intubation rates among neonates and children, but did not reach statistical significance (neonates RR=0.1, 95% CI 0.01, 1.68; children RR=0.49, 95% CI 0.01, 19.65). Post-extubation stridor was reduced in children (n=216: RR=0.53, 95% CI 0.28, 0.97) but not in neonates. In the neonatal studies, a lower re-intubation rate was seen only in high risk patients treated with multiple doses of steroids around the time of extubation. In three adult studies (total n=1047), no difference in post-extubation stridor (RR=0.86, 95% CI 0.57, 1.30) or re-intubation rates (RR=0.95, 95% CI 0.52, 1.72) was detected. Side effects were reported seldomly and could not be aggregated.
REVIEWER'S CONCLUSIONS: In neonates, there is a trend towards a reduced incidence of re-intubation in neonates receiving prophylactic dexamethasone prior to extubation. In children, prophylactic administration of dexamethasone prior to elective extubation reduces the incidence of post-extubation stridor, but the evidence is insufficient to conclude that rates of re-intubation are reduced. In adults, corticosteroids do not appear to reduce the need for re-intubation.
拔管后喘鸣可能会延长重症监护病房的住院时间,尤其是在气道梗阻严重且需要再次插管的情况下。然而,皮质类固醇可能会带来从高血压到高血糖等一系列不良反应,因此在广泛采用这种治疗方法之前,需要对其疗效进行更系统的评估。
确定皮质类固醇在预防或治疗危重症婴儿、儿童或成人拔管后喘鸣方面是否有效。
通过MEDLINE、EMBASE和CINAHL检索对照试验。检查所有已识别试验的参考文献,并联系纳入试验的作者以确认方法并识别其他潜在相关试验。
任何比较在重症监护病房接受气管插管机械通气的婴儿、儿童或成人中,通过任何途径给予皮质类固醇与安慰剂的随机对照试验。
两名评审员独立提取纳入研究的数据。主要结局是拔管后气管再次插管的发生率。将喘鸣的发生率作为次要结局进行检查。预先确定进行亚组分析,以比较拔管前预防性使用类固醇与拔管后治疗性使用类固醇的情况。分别对新生儿、儿科患者和成人进行比较。全程使用随机效应模型。两名评审员独立评估试验的方法学质量。
在识别出的251项研究中,只有7项符合纳入标准;3项针对成人,2项针对新生儿,3项针对儿童。除一项研究外,其他所有研究均考察了类固醇用于预防拔管后喘鸣的情况;其余一项研究关注儿童现有拔管后喘鸣的治疗。患者来自不同的内科/外科人群。拔管前至少静脉注射一次地塞米松是最常用的类固醇给药方案(新生儿和儿童均统一使用)。预防性干预倾向于降低新生儿和儿童的再次插管率,但未达到统计学意义(新生儿RR = 0.1,95%CI 0.01,1.68;儿童RR = 0.49,95%CI 0.01,19.65)。儿童拔管后喘鸣有所减少(n = 216:RR = 0.53,95%CI 0.28,0.97),但新生儿未减少。在新生儿研究中,仅在拔管前后接受多剂量类固醇治疗的高危患者中观察到较低的再次插管率。在三项成人研究(共n = 1047)中,未检测到拔管后喘鸣(RR = 0.86,95%CI 0.57,1.30)或再次插管率(RR = 0.95,95%CI 0.52,1.72)存在差异。很少报告副作用,且无法汇总。
在新生儿中,拔管前接受预防性地塞米松治疗的新生儿再次插管发生率有降低趋势。在儿童中,选择性拔管前预防性给予地塞米松可降低拔管后喘鸣的发生率,但证据不足以得出再次插管率降低的结论。在成人中,皮质类固醇似乎并未减少再次插管的需求。